Atrial Fibrillation (AFib) Quality Improvement Innovation Grants
The Heart Rhythm Society, in partnership with Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), announced a call for grant applications to support innovation and advancement in atrial fibrillation and stroke prevention research aimed at addressing National Quality Improvement (QI) priorities via demonstration projects/research. Through this effort, BIPI is providing $500,000 to support multiple grants to eligible applicants for proposals that aim to affect the behaviors and performance of patients, providers, and/or systems that when combined with existing standards and approaches to care, may enhance patient outcomes.
The Heart Rhythm Society received applications from U.S.-based health care providers, research scientists and Centers for Excellence focused on QI demonstration projects/research that improve risk screening and management of patients 18 years and older with a diagnosis of non-valvular atrial fibrillation, who are at risk for ischemic stroke. Finalists will present their proposals in front of an expert panel at Heart Rhythm 2016 in San Francisco, California on May 5, 2016. The winner(s) will go on to present their findings at Heart Rhythm 2017 in Chicago.
Total grants of up to $500,000 to eligible recipients for demonstration project(s)/research running no longer than 12 months.
Shared Decision-Making Tool for Thromboprophylaxis in Atrial Fibrillation
Mark H. Eckman, MD
University of Cincinnati, Cincinnati, OH
Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation
Steven A. Lubitz, MD, MPH
Massachusetts General Hospital, Boston, MA
Physician Perception of Stroke and Bleeding Risks and Impact on Oral Anticoagulant Utilization for Atrial Fibrillation
Nitin K. Kulkarni, MD
University of Texas Southwestern, Dallas, TX
Quality Improvement Measures to Improve Stroke Outcomes in Hispanic/Latino Patients with Atrial Fibrillation
Mark D. McCauley, MD, PhD
University of Illinois at Chicago, Chicago, IL
Improving Oral Anti-Coagulation Medication Adherence and Patient Engagement in non-valvular Atrial Fibrillation: Personal Health Record messaging and Family-Centered Care in patients with Cardiac Implantable Electronic Devices
Tammy Toscos, PhD
Parkview Health, Fort Wayne, IN
Application of the Chronic Disease Management to Atrial Fibrillation
George H. Crossley, MD, FHRS
Vanderbilt University, Nashville, TN
Final Presentations at HRS Scientific Sessions in San Francisco:
May 5, 2016
May 6, 2016
Presentation of Outcomes at 2017 HRS Scientific Sessions – Chicago, IL:
The Heart Rhythm Society requires: 1) that any research involving human subjects conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1992 Dec; 40 (4): 653-60) and Title 45, US Code of Federal Regulations, Part 46 Protection of Human Subjects, and 2) that any research involving animals will conform to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The sponsoring institution must provide evidence that all investigations engaged in are under the control of the institution and its investigational review board or other appropriate body. Documentation of regulatory approval by the Institutional Review Board, Institutional Animal Care and Use Committee, or other appropriate regulatory body must be provided to the HRS office prior to the release of funds.
The results of work carried out must be made publicly available through scientific channels according to the NIH Public Access Policy. An electronic or paper reprint of each published article should be furnished to the Heart Rhythm Society.
Awardees will be required to present data from their research at the Heart Rhythm Society’s 2017 Annual Scientific Sessions, taking place in Chicago, Illinois. In addition, a one-page abstract of the project must be submitted for distribution at this program.
A final financial report and a report summarizing research progress and accomplishments during the period of funding is to be submitted to the Heart Rhythm Society and Boehringer Ingelheim offices no later than the final day of support.
The funding organization, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) will contract with the winner(s) and manage the issuance of the grant awards and monitor the performance of the grant and milestone payments. Winners are subject to any grant/award compliance requirements of BIPI.
Boehringer Ingelheim Pharmaceuticals, Inc. will be able to obtain copy and negotiated rights to the results of the initiative.
Sponsored exclusively by: